[Federal Register Volume 78, Number 60 (Thursday, March 28, 2013)]
[Notices]
[Page 19017]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-07140]



[[Page 19017]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; 
Johnson Matthey Pharmaceutical Materials, Inc.

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 15, 2012, Johnson 
Matthey Pharmaceutical Materials, Inc., Pharmaceutical Service, 25 
Patton Road, Devens, Massachusetts 01434, made application by renewal 
to the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Nabilone (7379)............................  II
Hydrocodone (9193).........................  II
Alfentanil (9737)..........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
------------------------------------------------------------------------

    The company plans to utilize this facility to manufacture small 
quantities of the listed controlled substances in bulk and to conduct 
analytical testing in support of the company's primary manufacturing 
facility in West Deptford, New Jersey. The controlled substances 
manufactured in bulk at this facility will be distributed to the 
company's customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than May 28, 2013.

    Dated: March 20, 2013.
Joseph T. Rannazzisi,
 Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-07140 Filed 3-27-13; 8:45 am]
BILLING CODE 4410-09-P